| Eric A Bannec, MD | |
|
550 S Landmark Ave, Bloomington, IN 47403-3239 | |
| (812) 355-3255 | |
| (812) 333-5978 |
| Full Name | Eric A Bannec |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 32 Years |
| Location | 550 S Landmark Ave, Bloomington, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093710881 | NPI | - | NPPES |
| 200023880 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 01043608A (Indiana) | Secondary |
| 207R00000X | Internal Medicine | 01043608A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Indiana University Health Tipton Hospital Inc | Tipton, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Family Physicians, Inc. | 7911992797 | 424 |
News Archive
Montmorency tart cherry juice was found to help extend sleep time by 84 minutes among eight study participants, ages 50 and older who suffer from insomnia, according to a new pilot study published in American Journal of Therapeutics.
Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.
Researchers conducting a clinical trial to advance the treatment of multiple sclerosis successfully applied a new drug testing methodology which allows several treatment options to be trialled at once.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).
› Verified 8 days ago
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
Montmorency tart cherry juice was found to help extend sleep time by 84 minutes among eight study participants, ages 50 and older who suffer from insomnia, according to a new pilot study published in American Journal of Therapeutics.
Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.
Researchers conducting a clinical trial to advance the treatment of multiple sclerosis successfully applied a new drug testing methodology which allows several treatment options to be trialled at once.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).
› Verified 8 days ago
| Entity Name | Indiana University Health Southern Indiana Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013953983 PECOS PAC ID: 6204748197 Enrollment ID: O20040423000556 |
News Archive
Montmorency tart cherry juice was found to help extend sleep time by 84 minutes among eight study participants, ages 50 and older who suffer from insomnia, according to a new pilot study published in American Journal of Therapeutics.
Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.
Researchers conducting a clinical trial to advance the treatment of multiple sclerosis successfully applied a new drug testing methodology which allows several treatment options to be trialled at once.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric A Bannec, MD 250 N Shadeland Ave Ste 200, Indianapolis, IN 46219-4959 Ph: (317) 962-3834 | Eric A Bannec, MD 550 S Landmark Ave, Bloomington, IN 47403-3239 Ph: (812) 355-3255 |
News Archive
Montmorency tart cherry juice was found to help extend sleep time by 84 minutes among eight study participants, ages 50 and older who suffer from insomnia, according to a new pilot study published in American Journal of Therapeutics.
Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.
Researchers conducting a clinical trial to advance the treatment of multiple sclerosis successfully applied a new drug testing methodology which allows several treatment options to be trialled at once.
Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.
VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).
› Verified 8 days ago
Wai Pok Vernon Chan, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-676-4102 Fax: 812-676-4106 | |
Dr. Kevin Edward Zawacki, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1312 W. Arch Haven Avenue, Bloomington, IN 47403 Phone: 812-676-4144 Fax: 812-339-8344 | |
Mr. Rana Zouveenoor Tariq, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1312 W Arch Haven Ave, Bloomington, IN 47403 Phone: 812-676-4144 | |
Dr. Samuel W Kimani, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 550 S Landmark Ave, Bloomington, IN 47403 Phone: 812-331-3400 Fax: 812-332-7265 | |
Dr. Simeon Zou, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 583 S Clarizz Blvd, Bloomington, IN 47401 Phone: 812-676-4460 Fax: 812-355-4092 | |
Shelby Renee Tipton, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 2905 N Stone Carver Dr, Bloomington, IN 47404 Phone: 812-676-4715 | |
Ms. Louise Anne Owens, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 500 S Madison St, Bloomington, IN 47403 Phone: 812-334-3303 Fax: 812-334-0842 |